Format

Send to

Choose Destination
See comment in PubMed Commons below
Vet Comp Oncol. 2015 Sep;13(3):203-17. doi: 10.1111/vco.12037. Epub 2013 May 8.

Combined zoledronic acid and meloxicam reduced bone loss and tumour growth in an orthotopic mouse model of bone-invasive oral squamous cell carcinoma.

Author information

1
Department of Veterinary Biosciences, College of Veterinary Medicine, Columbus, OH, USA.
2
Small Animal Imaging Center Shared Resource, Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA.

Abstract

Oral squamous cell carcinoma (OSCC) is common in cats and humans and invades oral bone. We hypothesized that the cyclooxygenase (COX)-2 inhibitor, meloxicam, with the bisphosphonate, zoledronic acid (ZOL), would inhibit tumour growth, osteolysis and invasion in feline OSCC xenografts in mice. Human and feline OSCC cell lines expressed COX-1 and COX-2 and the SCCF2 cells had increased COX-2 mRNA expression with bone conditioned medium. Luciferase-expressing feline SCCF2Luc cells were injected beneath the perimaxillary gingiva and mice were treated with 0.1 mg kg(-1) ZOL twice weekly, 0.3 mg kg(-1) meloxicam daily, combined ZOL and meloxicam, or vehicle. ZOL inhibited osteoclastic bone resorption at the tumour-bone interface. Meloxicam was more effective than ZOL at reducing xenograft growth but did not affect osteoclastic bone resorption. Although a synergistic effect of combined ZOL and meloxicam was not observed, combination therapy was well-tolerated and may be useful in the clinical management of bone-invasive feline OSCC.

KEYWORDS:

bone invasion; bone resorption; feline; meloxicam; oral squamous cell carcinoma; zoledronic acid

PMID:
23651067
PMCID:
PMC3751980
DOI:
10.1111/vco.12037
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Wiley Icon for PubMed Central
    Loading ...
    Support Center